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Systematic reviews use scientific methods to assemble and
critically appraise relevant studies that address a specific clinical
question [1]. Meta-analysis is a type of systematic review that uses
quantitative methods to combine data from separate studies. Like
all scientific studies, meta-analysis results should be reproducible.
An independent group of investigators should be able to assemble
the same studies, extract the same data, and use the same
statistical methods to produce the same result.
The term meta-analysis was first used by Gene Glass in 1976, to
distinguish this analysis from primary and secondary (re-analysis)
of data [2]. Karl Pearson was one of the first to apply meta-
analysis, when in 1904 he combined the results of five studies and
showed that inoculations for enteric fever were ineffective [3].
Subsequently, a number of reports appeared describing tech-
niques for combining data across studies. However, it was not
until the 1970s that meta-analysis came to be used routinely, at
first in the social sciences. More recently it has become common
to use meta-analysis in the medical sciences, including nephrol-
ogy.
WHY META-ANALYSIS?
There are a number of reasons to carry out a meta-analysis
(Table 1). With the rapid growth of medical literature, it has
become difficult, if not impossible, for clinicians to review and
interpret the results of all pertinent studies to make sound clinical
decisions. Clinicians and policy makers must therefore rely on
reviews to summarize the results of studies. Traditionally, this role
has been fulfilled by narrative reviews written by recognized
experts in the particular field. However, narrative reviews are
inherently biased. In contrast, systematic reviews are designed to
summarize the results of a large numbers of studies, and to
eliminate as much bias as possible in their interpretation. The use
of quantitative methods in meta-analysis is designed to aid in this
process. The use of quantitative methods in systematic reviews
cannot overcome a systematic review that is flawed or biased. The
adage “garbage in, garbage out” applies to meta-analyses of
studies from poorly conducted systematic reviews as well. On the
other hand, a narrative review is even more susceptible to
potential bias, because no justification is required for excluding or
discounting studies arbitrarily.
Most often meta-analysis is used to test a particular hypothesis
that was tested in a number of separate clinical trials. In this case,
meta-analysis serves to increase the statistical power of studies by
increasing the combined sample size. However, meta-analysis can
also increase the generalizability of the results of individual
studies, by examining the overall effect of a therapy in a number
of different clinical settings and patient populations.
Often overlooked is the hypothesis generating capability of
meta-analysis. This is analogous to the post-hoc subgroup analysis
that is often carried out to analyze the results of an individual
clinical trial. If there are a sufficiently large number of studies, it
may be possible to correlate the effect of a therapy with the way
in which therapy was delivered (such as type of drug or timing of
the therapy) or with patient population characteristics (such as
age, gender, race, or type of underlying disease). For example, it
may not be apparent from a single trial that a particular therapy
is more effective in men than in women. However, a meta-analysis
that includes separate studies in men and women may suggest that
this is the case. This may then suggest the need for additional
studies to directly compare the effect of the therapy in men versus
women. Looking for reasons for differences in the results of
clinical trials is rarely conclusive. As in the case with subgroup
analysis of clinical trial results, the possibility of finding associa-
tions due to chance increases with the number of such associations
that are examined. Hence, this type of analysis should be consid-
ered to be hypothesis generating, rather than hypothesis testing.
The results of meta-analysis can be used to aid in the design of
large-scale trials. For example, the overall effect of a therapy
calculated across several different studies in a meta-analysis can
be used to estimate the sample size needed for a large, multi-
center trial. In addition, as suggested above, correlations between
various study or patient characteristics and the effectiveness of
treatment in a meta-analysis may suggest the need for additional
studies in targeted populations.
META-ANALYSIS TECHNIQUES
A good meta-analysis is usually the result of a close collabora-
tion between clinician and statistician [4]. However, it is helpful
for clinicians to have some understanding of meta-analysis tech-
niques. Here I will give a brief overview. More details can be
found in the references and in textbooks [5, 6].
A number of techniques have been developed to combine the
results of clinical trials. Most meta-analyses combine simple and
unambiguous outcomes. However, this need not always be the
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case. If reports of primary studies adequately describe a compli-
cated outcome, such reports can usually be combined in a
quantitative fashion.
Vote counting method
Although vote counting is perhaps the simplest, it has major
limitations [7]. Vote counting simply sums the number of studies
with a “yes or no” result, and the winner takes all. An inherent
limitation of vote counting is that it does not take into account the
“margin of victory.” The result is just as positive if 51 out of 100
studies report a positive effect as it is if 99 out of 100 studies are
positive. Likewise, vote counting does not take into account the
number of subjects in the individual trials. A study with 10
participants counts just as much in the final result as a study with
10,000 participants. In addition, vote counting has limited statis-
tical power, because it does not take into account the magnitude
of differences in the treatment effect within each study. Vote
counting may only be useful when the studies do not allow
calculation of a treatment effect.
Differences between treatment and control
There are several different methods for calculating the differ-
ences between treatment and control, that is, the magnitude of the
treatment effect or the effect size. The effect size can be based on
dichotomous outcomes (such as risk differences, relative risks, or
odds ratios) or on numeric values (such as differences between
treatment and control or correlations). When different units of
measure are used in different studies, it may be necessary to
normalize the effect sizes before combining them. One method is
to divide the difference between treatment and control by the SD.
A particular treatment effect then becomes the number of SDs
more (or less) than control. This has the advantage of allowing
trials reporting outcomes in different units (“apples and oranges”)
to be combined, but the disadvantage of making it difficult for
clinicians to judge the clinical relevance of the magnitude of the
combined treatment effect. Effect sizes can be calculated from P
values.
Treatment effects of individual studies
The treatment effects of individual studies can be combined
using one of several techniques. Generally, the treatment effect of
each individual study is given a pre-determined weight, so studies
do not contribute equally to the final result (unlike vote counting).
The most common method is to weight the treatment effect in
each study by its inverse variance. This gives relatively more
weight to studies having less variability and to studies having a
larger number of subjects. Weighting by inverse variance has the
advantage of being objective. This cannot be said of another
common approach, weighting studies by quality. Quality is a
feature that is more in the eye of the beholder, as evidenced by the
large number of different quality indexes that have been proposed
to judge study quality. Most investigators agree on a number of
characteristics that suggest a good study, such as masking of
subjects, random allocation, use of intention-to-treat analysis, etc.
However, it is more difficult to judge the relative merit of these
different features and thereby derive a single composite quality
index. Should the masking of subjects be given equal weight as
random allocation? There is as yet no consensus for how best to
weight studies for quality. It is also possible to weight studies using
both inverse variance and quality.
Fixed and random effects models
The optimal method for combining the treatment effects of
studies has been much debated. Two methods (or “models”) are
used most often: the fixed effects and the random effects models.
The fixed effects model assumes that the studies being combined
are homogeneous, and studies differ only because they use a
sample of observations rather than the whole population of
observations itself. The random effects model does not make that
assumption, but assumes only that the sample of studies are
representative of a larger population of all such studies. In the
random effects model differences in the studies are due not only
to differences in sampling of the treatment effects, but also to
differences in the studies themselves [8]. Thus, the fixed effects
model can be thought of as giving a result pertinent to “these
studies” compared to results for “studies like these” from the
random effects model [9]. The confidence intervals resulting from
combining studies with the random effects model are typically
wider (indicating more uncertainty of the result), and are never
narrower than those from the fixed effects model. In the fixed
effects model larger studies receive relatively more weight than
smaller studies, compared to the random effects model. The
random effects model may be more appropriate for combining
large numbers of trials, while the fixed effects model may be better
suited for combining a small number of studies, such as two or
three. Although the fixed and random effects models are most
commonly used, other approaches to combining studies have been
developed [10, 11].
Meta-analysis, especially using the fixed effects model, assumes
that trials are homogeneous in every way that could affect the
outcome. This assumption can and should be tested [8]. However,
the statistical tests for homogeneity of study results are relatively
insensitive, that is, have low statistical power. Often explaining
variability in the results of studies to generate hypotheses can be
just as important as combining their results to test hypotheses. In
regression analysis the dependent variable becomes the treatment
effect, generally weighted by inverse variance, and various study,
treatment or patient characteristics can be used as independent or
explanatory variables. Study quality indicators can be used either
as one or more independent variables or as a regression weight.
Regression analysis can be used to explain differences in results
that are either continuous or dichotomous.
RELIABILITY OF META-ANALYSIS
Most clinicians and investigators consider the gold standard for
determining the effectiveness of therapy to be the large, random-
ized, controlled trial. However, even very large randomized trials
can produce inconclusive results. Nevertheless, much of the
controversy surrounding the validity of meta-analysis has come
from comparisons of meta-analysis results with the results of
subsequent large clinical trials.
Table 1. Reasons for doing a meta-analysis
1. Collate a large number of studies
2. Reduce bias inherent in a narrative review
3. Increase statistical power: test hypotheses
4. Define reasons for study differences: generate hypotheses
5. Determine the need for additional trials
6. Calculate sample size needed for additional trials
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There have been several recent attempts to validate the results
of meta-analysis compared to those of large randomized, con-
trolled trials. Recently LeLorier and co-workers compared the
results of meta-analyses published in four major medical journals
with those of subsequent, large, randomized, controlled trials [12].
They identified 12 large, randomized, controlled trials and 19
meta-analyses, and were able to compare 40 primary and second-
ary outcomes. The positive predictive value of meta-analysis was
68% and the negative predictive value was 67%. Overall, the
results of the large, randomized, controlled trials were not accu-
rately predicted 35% of the time, although there was a statistically
significant difference in results in only 5 of 40 comparisons (12%).
In no instance was there a divergence where the meta-analysis and
the randomized trial gave statistically significant results in the
opposite direction.
Borzak and Ridker examined reasons why the results of meta-
analysis differed from those of large, randomized, controlled trials
[13]. In the first example, the combined results of seven trials of
intravenous nitroglycerin and three trials of nitroprusside (N 5
2000 patients) indicated that nitrates significantly reduced mor-
tality after myocardial infarction [14]. Subsequently two large
randomized, controlled trials failed to confirm the results of the
meta-analysis [15, 16]. There were several possible explanations
for this apparent discrepancy: (1) In the large-scale trials over one
half of the control patients also received nitrates, possibly reduc-
ing differences between the two groups. (2) The number of
patients in the meta-analysis was relatively small, reducing the
reliability of its conclusions. (3) The trials in the meta-analysis
were all completed several years before the large-scale trials. In
the mean time the adoption of new therapies led to a 50%
decrease in mortality from myocardial infarction. Thus, nitrates
may have been more effective in the earlier trials, and less so in
the later large-scale trials.
Often it is possible to determine reasons for discrepancies
between meta-analysis of small trials compared to the results of
large randomized, controlled trials. Cappelleri and co-workers
compared the results of pooled small trials with those of “large”
trials [17]. Using a random effects model, they found agreement
between 79 meta-analyses and large trials in 90% of comparisons,
when large trials were defined by size (N . 1000 patients), and in
82% when large trials were defined by statistical power. Twice as
many disagreements were found when a fixed effects model was
used. Of 15 comparisons that were statistically different (using the
power approach to define large trials), in 9 the large trials failed
to confirm the meta-analysis results, in 2 the large trials showed an
effect of treatment not evident in the meta-analysis, and in 4 both
indicated beneficial effects of treatment, albeit of a different
magnitude. In 5 of the 15 disparities, significant differences were
related to differences in the rate of events in the control popula-
tions. Statistical evidence of publication bias could be detected in
at least 1, and possibly 3 of the 15 disparities. In another 4
instances there were specific protocol or study differences that
were likely to explain differences in the results. In only 5 of the 15
instances were there no apparent reasons for the different results,
and in 2 of these the differences were not clinically important,
since the conclusions were the same but of different magnitude.
The authors concluded that unexplained, clinically relevant dif-
ferences between meta-analysis and large randomized, controlled
trials are rare [17].
There are several reasons why the results of meta-analysis may
not predict those of large, randomized, controlled trials: (1) Times
change. Usually, meta-analyses of small trials are performed
before large, randomized, controlled trials are carried out. If the
overall care of patients improves, the outcome in the control
group in the large-scale trial may be better than that of the control
groups in the smaller trials included in the meta-analysis. As a
result, the efficacy of treatment may be relatively less in the
large-scale trial. (2) Publication, file-drawer, or language bias. If
the trials in the meta-analysis are not representative of all trials
carried out, then the result may be biased. It is more likely that a
small study will not be published than a large-scale study. (3)
Differences in the individual trials. Heterogeneity in patient
populations (such as age, gender, race, and type of renal disease)
and study methods (such as dose, duration, and trial design) may
cause the results of studies to differ. Large-scale trials are likely to
be designed differently than smaller trials. For example, treatment
protocols in large trials are more likely to be simpler than those of
small trials, to enable enrollment to take place at multiple centers
under varied conditions. (4) Poor study quality. Like any scientific
study, the results of meta-analysis can only be as good as the
methods used to generate them. (5) Chance. As the number of
meta-analyses increases, the likelihood that some will be positive
as the result of chance (at P , 0.05) increases.
THREATS TO THE VALIDITY OF META-ANALYSIS
Meta-analysis assumes that the included trials are representa-
tive of all pertinent trials. When this is not the case, the results of
the meta-analysis can be erroneous. The tendency of journal
editors to favor publication of studies with “positive” outcomes
can result in serious publication bias. A related problem occurs
when investigators fail to submit “negative” results for publica-
tion, believing that publishing may be difficult, time consuming,
and perhaps even futile. This has been called “file-drawer bias.”
Publication and/or file-drawer bias can influence the results of
meta-analysis [17–19]. Publication bias is a problem that is not
unique to meta-analysis, but is rather a problem of interpreting
trial results in general. In fact, meta-analysis has served a useful
purpose in defining the problem and suggesting ways of dealing
with it.
Techniques have been developed to assess the likelihood of
publication bias. One technique uses funnel plots (Fig. 1) [20].
Funnel plots take advantage of the fact that unpublished studies
are more likely to be small. A plot of treatment effects on the
y-axis versus the study sample size on the x-axis should yield a
funnel centered about a horizontal line representing the pooled
treatment effect across all studies. The base of the funnel is wide
due to more variability in treatment effects when study sample
sizes are relatively small. The top of the funnel is narrower due to
less variability in treatment effects when study sample sizes are
larger. When there is publication bias, part of the funnel near the
base may appear to be missing, because fewer small, negative
versus positive studies were published. An analogous plot uses
study variance in place of sample size. Formal statistical tech-
niques have been developed to examine positive correlations
between estimates of treatment effects and their variances [21].
One method for detecting file-drawer bias estimates the number
of studies with zero effect that would be needed to reduce the
combined p-value to a non-significant level [22]. A very large
number of required studies makes it unlikely that so many
unpublished studies would exist. However, this technique is based
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on the assumption that unpublished studies have zero treatment
effect.
Inadequate literature search strategies can threaten the validity
of meta-analysis. It is not necessary to include all pertinent
studies, but it is important that the selected studies are a
representative sample of all studies. Whether unpublished studies
should be included in a meta-analysis is controversial. Some
authors stress the importance of including all study results,
published or unpublished. However, unpublished studies may be
unpublished because they are flawed. The peer-review process is
an important step designed to ensure that all pertinent informa-
tion is given to the reader, and by-passing this process may be
dangerous. Including unpublished studies also raises a number of
practical concerns. In the absence of trial registries it may be very
difficult to locate all pertinent clinical trials, and it is conceivable
that those located will be different than those not located. In
addition, the time, effort and expense of locating unpublished
studies may be prohibitive. Finally, the concept that meta-analysis
results should be reproducible is seriously challenged by the
inclusion of unpublished studies that other investigators may not
have ready access to.
Excluding studies published in certain languages can also lead
to a “Tower of Babel” bias. One study examined the effects of
language publication bias on the results of meta-analysis [23].
These investigators reviewed all meta-analyses published in eight
medical journals between 1991 and 1993. Out of 36 meta-analyses,
the exclusion of studies based on language produced results
different from those that would have been obtained if studies in
all languages had been included only once [23].
Often, care of patients improves in ways that are not related to
a therapy being tested in clinical trials. As a result, outcomes may
change over time among controls. Improvements in medical care
that reduce adverse outcomes may reduce the treatment effect,
and make the effectiveness of therapy appear to diminish in more
recent studies (Table 2).
JUDGING THE QUALITY OF META-ANALYSIS
In many ways a meta-analysis can be thought of as a reproduc-
ible, scientific, study. Indeed, a meta-analysis deserves the same
scrutiny that is generally applied to individual clinical, studies.
There are several characteristics that suggest a meta-analysis of
high quality (Table 3). The purpose or hypothesis should be
clearly stated. A good meta-analysis includes as many relevant
studies as possible, and a description of the search techniques
should be clear. In the case of electronic searches, the search
terms and databases should be specified. The inclusion and
exclusion criteria used to determine which trials were analyzed
should also be clearly stated. Some assessment of study quality
should usually be made. How data were extracted should be clear,
that is, by one or more independent reviewers. Ideally, the
investigators should be masked, although this may be difficult to
accomplish if the studies are well known.
The methods used in combining studies should be indicated.
Was a fixed effects model or a random effects model used? Some
effort to determine whether the studies were homogeneous
should also be made. If the studies were not homogeneous, this
should be taken into account in the analysis and interpretation of
the results. A search for reasons why studies produced different
results is often very important. Were there differences in the
patients studied, how the intervention was applied, the duration of
follow-up, etc.? Were studies weighted by inverse variance, qual-
ity, or some combination of the two methods? Finally, was a
sensitivity analysis carried out to see how results might have been
affected by the assumptions that were made? Were the results
similar if one or more outliers were deleted?
ROLE OF MULTIPLE META-ANALYSES
Much misunderstanding has resulted from the tendency to
think of meta-analysis as the final word. It is probably better to
view meta-analysis as a technique, or tool that can be applied in
many different ways to different samples of studies. More than
one meta-analysis on the same subject may be both appropriate
and desirable. The most cogent reason for carrying out additional
meta-analysis is that new pertinent studies may be published
which will help to resolve issues. In fact, some have advocated the
use of cumulative meta-analysis, where the same meta-analysis is
repeated after each new applicable clinical trial is carried out. In
this way investigators can best judge the need for additional trials.
For example, it has been shown that a cumulative meta-analysis
may have made the beneficial effects of thrombolytic therapy after
Table 2. Threats to the validity of a meta-analysis
1. Publication bias
2. File-drawer bias
3. Language bias
4. Exclusion of unpublished studies
5. Study heterogeneity
6. Trends over time that alter treatment effects
7. Poor quality of included studies
Fig. 1. Example of a funnel plot to explore
publication bias. The vertical axis represents
outcome systolic blood pressure minus baseline
systolic blood pressure in the high-sodium
group minus the low sodium group. Horizontal
lines are at zero and at the mean treatment
effect. The lack of points above the mean
treatment effect at low effective sample sizes is
most likely due to publication bias.
(Reproduced with permission, MIDGLEY JP,
MATTHEW AG, GREENWOOD CMT, LOGAN
MG: Effect of reduced dietary sodium on blood
pressure. JAMA 275:1590–1597, 1996).
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myocardial infarction apparent sooner, thereby obviating the need
for additional trials that may have subjected some patients to
unnecessary risk [24, 25]. In addition, the same studies can be
analyzed in different ways, using for example, different techniques
and endpoints. Although the argument can be made that there are
currently too many review articles and chapters for the practicing
clinician to read, a better argument can be made for replacing at
least some narrative reviews with systematic reviews.
META-ANALYSIS IN NEPHROLOGY
Meta-analysis is becoming a frequently used tool in nephrology,
and several different issues have been addressed using meta-
analysis. A Medline search with key words and major subject
headings “meta-analysis” and “kidney”, along with a search of
bibliographies in recent reviews, located 30 meta-analyses dealing
with issues pertinent to nephrology (Table 4). Excluded from this
list were several meta-analyses dealing with hypertension and its
effect on cardiovascular disease. Two meta-analyses were pub-
lished before 1990, 14 between 1990 and 1993, and 14 between
1994 and 1997.
There have been seven meta-analyses of studies examining the
effects of antihypertensive agents on the kidney. Experiments in
animal models of diabetic and nondiabetic renal disease suggested
that agents which reduced not only systemic blood pressure, but
also intraglomerular capillary pressure were particularly effective
in reducing albuminuria and renal injury. The concept that not all
antihypertensive agents are equal in their ability to reduce renal
injury led to a large number of clinical trials comparing the effects
of angiotensin converting enzyme (ACE) inhibitors and other
antihypertensive agents. Most of the early studies used urinary
protein excretion as a surrogate endpoint, but more recent
long-term trials have also measured changes in glomerular filtra-
tion rate.
In 1993 we published results of a meta-analysis showing that
blood pressure reduction was associated with reduced proteinuria
and improved renal function, and that ACE inhibitors had an
additional beneficial effect on protein excretion and renal func-
tion that was independent of blood pressure reduction per se [26].
We carried out a similar meta-analysis comparing the effects of
antihypertensive agents in diabetic and non-diabetic renal disease,
and concluded that the beneficial effects of antihypertensive
agents were similar in these two populations [27]. De Jong and
co-workers have also examined the effects of antihypertensive
agents on proteinuria and renal function in studies of diabetic and
non-diabetic renal disease [28, 29]. They concluded that ACE
inhibitors had a greater antiproteinuric effect than other antihy-
pertensive agents, and that the antiproteinuric effect of ACE
inhibitors was independent of blood pressure reduction. These
results were also confirmed by another group of investigators [30,
31]. Since these earlier meta-analyses, several large-scale trials
have been carried out. The results of these trials have largely
confirmed those of the meta-analyses. In addition, the larger
numbers of patients from the more recent trials have now made it
possible for Giatras and co-workers to examine the effects of ACE
inhibitors on the development of nondiabetic, end-stage renal
disease [32]. They also concluded that ACE inhibitors are more
effective than other antihypertensive agents in reducing the
development of nondiabetic, end-stage renal disease. Altogether,
the results of meta-analysis and large-scale, clinical trials examin-
ing the effects of antihypertensive agents on the kidney have been
quite consistent.
For decades it has been hypothesized that dietary protein
restriction might be beneficial in patients with progressive renal
disease. Indeed, as early as 1918 Fanz Volhard wrote of using a
low protein diet to ameliorate the signs and symptoms of uremia
[33]. More recently, several randomized, controlled clinical trials
were carried out to examine the effects of dietary protein restric-
tion on the rate of decline in renal function. In 1992, Fouque and
co-workers published a meta-analysis of trials examining the
effects of dietary protein restriction in 890 patients with non-
diabetic renal disease [34]. They examined the effect of protein
Table 3. Quality features to look for in a meta-analysis
1. Statement of purpose
2. Search strategy: databases and key words used
3. Inclusion and exclusion criteria
4. Assessment of study quality
5. Data extraction: investigators & methods
6. Methods used to combine treatment effects
7. Tests for study homogeneity
8. Reasons for differences between studies
9. Weighting studies: inverse variance, quality
10. Sensitivity analysis of assumptions
Table 4. Some examples of meta-analysis in nephrologya
Effects of Antihypertensive Agents on Proteinuria and Renal Function
Diabetic and non-diabetic renal disease 1992 de Jong [28]
Diabetic renal disease 1992 Bergemann [31]
Diabetic renal disease 1993 Kasiske [26]
Diabetic renal disease 1994 Bohlen [30]
Diabetic and non-diabetic renal disease 1995 Maki [27]
Diabetic and non-diabetic renal disease 1995 Gansevoort [29]
Diabetic and non-diabetic renal disease 1997 Giatras [32]
Effects of Dietary Protein Restriction on Renal Death
Diabetic renal disease 1992 Fouque [34]
Diabetic and non-diabetic renal diseases 1996 Pedrini [36]
Renal Disease-Specific Treatment
Lupus nephritis 1984 Felson [40]
Lupus nephritis 1997 Bansal [41]
IgA nephropathy 1990 Schena [42]
Membranous nephropathy 1994 Couchoud [37]
Membranous nephropathy 1995 Imperiale [38]
Membranous nephropathy 1995 Hogan [39]
Renovascular hypertension 1996 Blaufox [43]
Acute Renal Failure
Parenteral nutrition 1988 Naylor [44]
Contrast nephropathy 1993 Barrett [45]
Renal Transplantation
Immunoglobulin therapy for CMV 1991 Glowicki [46]
Efficacy of cyclosporine 1990 Walker [47]
Efficacy of OKT3 1992 Carrier [48]
Cyclosporine withdrawal 1993 Kasiske [49]
Steroid withdrawal 1993 Hricik [50]
Mechanisms of Chronic Renal Injury
Reduced renal mass 1995 Kasiske [51]
Proteinuria 1996 Perna [52]
Other Therapies and Issues in Renal Disease
Antibiotics for urinary tract infection 1991 Leibocici [53]
Sepsis and dialysis catheters 1993 Jernigan [54]
Netilmicin pharmacokinetics 1993 Keller [55]
Renal colic 1994 Labrecque [56]
Diagnosis of Wegener’s granulomatosis 1995 Rao [57]
Lipid-lowering therapy 1995 Massy [58]
a Studies on hypertension per se were not included.
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restriction on “renal death,” that is, death, dialysis or renal
transplantation, and concluded that low protein diet was effective.
Subsequently, the Modification of Diet in Renal Disease
(MDRD) study examined the effects of dietary protein restriction
in 840 patients with non-diabetic renal disease [35]. This well-
designed, multicenter trial had adequate statistical power to
determine whether diet would slow the rate of renal disease
progression. In the group of patients with the most severe renal
disease (Study 2) dietary protein restriction had no effect on renal
disease progression. In the group of patients with less severe renal
disease (Study 1) the effects of dietary protein restriction also
failed to reduce the rate of renal disease progression [35]. Neverthe-
less, there appeared to be a trend to a reduced rate of progression
from the low protein diet in Study 1. Pedrini and coworkers then
carried out another meta-analysis that included the MDRD trial
results as well as studies in patients with diabetic nephropathy [36].
They concluded that dietary protein restriction slows the progression
of both diabetic and non-diabetic renal diseases [36].
Thus, clinicians are left with an apparent dilemma. The largest
clinical trial (with adequate statistical power to test the hypothe-
sis) was inconclusive, while two meta-analyses suggested low
protein diet was beneficial. One of the differences in the large-
scale clinical trial and the two meta-analyses is the endpoint
examined. In Study 1 of the MDRD the primary endpoint was the
change in glomerular filtration rate, while both meta-analyses
used renal death as the primary endpoint. It is possible that a low
protein diet may affect renal death by reducing the signs and
symptoms of uremia without altering the rate of change in
glomerular filtration rate. Moreover, the studies were not blinded,
so the decision to begin renal replacement therapy may have been
influenced by the physician’s knowledge of which diet their
patients were receiving. However, in Study 2 of the MDRD trial
there was no trend for renal death to be reduced in the very low
protein diet group. There are also other differences between the
MDRD trial and the trials included in the meta-analyses. Differ-
ences in the patient populations studied (for example, the pro-
portion with proteinuric and non-proteinuric renal disease) may
have influenced the results. Neither of the two meta-analyses
systematically examined how heterogeneity in the individual stud-
ies may have affected the results. One conclusion was apparent
from all of these trials. The magnitude of the effect of dietary
protein restriction is relatively small. Thus, the number of patients
needed to show a statistically significant effect, if such an effect
truly exists, is very large.
There have been several meta-analyses examining studies of
therapy for specific renal diseases (Table 4). Three meta-analyses
have examined treatment for membranous nephropathy [37–39].
Couchoud, Laville and Boissel examined the effects of any
treatment on both renal death and complete remissions in eight
controlled trials (N 5 526 patients) [37]. They found no reduction
in renal death or complete remission of proteinuria, although the
numbers of patients with these endpoints were small, reflecting
the small size and the relatively short duration of follow-up in the
studies. Results with the surrogate endpoints “impairment of
renal function” and “improvement in proteinuria” favored treat-
ment. Imperiale, Goldfarb and Berns examined the effects of
cytotoxic agents in achieving a complete remission from protein-
uria in five trials (N 5 228 patients) [38]. There were no placebo
control groups in these trials. The relative risk of a complete
remission with cytotoxic agents was 4.6 (95% confidence interval
2.2 to 9.3) and the number needed to treat to achieve a complete
remission was 4.7.
Hogan and co-workers also carried out a meta-analysis of
treatment for idiopathic membranous nephropathy [39]. They
found that the relative chance for complete remission in four trials
with corticosteroids versus no treatment (N 5 351 patients) was
1.55, 95% confidence interval, 0.99 to 2.44 (P . 0.1). The relative
chance of complete remission in three trials with alkylating agents
versus no treatment (N 5 142 patients) was 4.8, 95% confidence
interval 1.44 to 15.96 (P , 0.05). Neither corticosteroids nor
alkylating agents improved renal survival.
The results of the three meta-analyses of therapy for idiopathic
membranous nephropathy have been useful in defining the issues
and suggesting areas for future investigation. Together they
suggest there is little evidence that any therapy improves renal
survival. However, therapy (especially with alkylating agents)
seems to reduce proteinuria. Since there are many other studies
suggesting that the degree of proteinuria is a predictor of long-
term outcome in patients with renal disease, it is possible that the
failure to show improved renal survival may only reflect the
relative small numbers of patients and short duration of follow-up
in these trials. Therefore, additional large-scale, long-term trials
are needed.
A number of other meta-analyses have been used to synthesize
clinical trials of interest to nephrologist (Table 4). In general,
these meta-analyses have helped clinicians to better judge the
strength of the evidence from clinical trials. As the number of
clinical trials grow, and as clinicians gain a better understanding of
how to interpret meta-analysis results, meta-analysis will likely
play an increasingly useful role in nephrology.
ACKNOWLEDGMENTS
I am grateful for the helpful suggestions from Thomas A. Louis, Ph.D.,
and Jennie Ma, Ph.D.
Reprint requests to Bertram L. Kasiske, M.D., Division of Nephrology,
Department of Medicine, Hennepin County Medical Center, 701 Park Avenue
South, Minneapolis, Minnesota 55415, USA.
E-mail: kasis001@tc.umn.edu
REFERENCES
1. COOK DJ, MULROW CD, HAYNES RB: Systematic reviews: Synthesis of
best evidence for clinical decisions. Ann Intern Med 126:376–380, 1997
2. GLASS GV: Primary, secondary, and meta-analysis. Educational Re-
searcher 5:3–8, 1976
3. PEARSON K: Report on certain enteric fever inoculation statistics. Br
Med J 3:1243–1246, 1904
4. BAILAR JD III: The promise and problems of meta-analysis. (editorial;
comment) N Engl J Med 337:559–561, 1997
5. The Handbook of Research Synthesis. New York, Russell Sage Foun-
dation, 1994
6. GLASS GV, MCGAW B, SMITH ML: Meta-Analysis in Social Research.
Beverly Hills, Sage Publications, 1981
7. BUSHMAN BJ: Vote-counting procedures in meta-analysis, in The
Handbook of Research Synthesis, edited by COOPER H, HEDGES LV,
New York, Russell Sage Foundation, 1994, p 193
8. DERSIMONIAN R, LAIRD N: Meta-analysis in clinical trials. Controlled
Clin Trials 7:177–188, 1986
9. LOUIS TA: Meta-analysis of clinical studies: The whole is greater than
the sum of its parts. (editorial) Transfusion 33:698–700, 1993
10. HARDY RJ, THOMPSON SG: A likelihood approach to meta-analysis
with random effects. Stat Med 15:619–629, 1996
11. LOUIS TA, ZELTERMAN D: Bayesian approaches to research synthesis,
in The Handbook of Research Synthesis, edited by COOPER H, HEDGES
LV, New York, Russell Sage Foundation, 1994, p 411
Kasiske: Meta-analysis as a clinical tool in nephrology824
12. LELORIER J, GREGOIRE G, BENHADDAD A, LAPIERRE J, DERDERIAN F:
Discrepancies between meta-analyses and subsequent large random-
ized, controlled trials. N Engl J Med 337:536–542, 1997
13. BORZAK S, RIDKER PM: Discordance between meta-analyses and
large-scale randomized, controlled trials. Examples from the manage-
ment of acute myocardial infarction. Ann Intern Med 123:873–877, 1997
14. YUSUF S, COLLINS R, MACMAHON S, PETO R: Effect of intravenous
nitrates on mortality in acute myocardial infarction: An overview of
the randomised trials. Lancet 1:1088–1092, 1988
15. GRUPPO ITALIANO PER LO STUDIO DELLA SOPRAVVIVENZA NELL’INFARTO
MIOCARDICO: Effects of lisinopril and transdermal glyceryl trinitrate
singly and together on 6-week mortality and ventricular function after
acute myocardial infarction. Lancet 343:1115–1122, 1994
16. FOURTH INTERNATIONAL STUDY OF INFARCT SURVIVAL COLLABORA-
TIVE GROUP: A randomised factorial trial assessing early oral capto-
pril, oral mononitrate, and intravenous magnesium sulphate in 58,050
patients with suspected acute myocardial infarction. Lancet 345:669–
685, 1995
17. CAPPELLERI JC, IOANNIDIS JPA, SCHMID CH, DE FERRANTI SD,
AUBERT M, CHALMERS TC, LAU J: Large trials vs meta-analysis of
smaller trials. How do their results compare? JAMA 276:1332–1338, 1996
18. EASTERBROOK PJ, BERLIN JA, GOPALAN R, MATHEWS DR: Publica-
tion bias in clinical research. Lancet 337:867–872, 1991
19. DICKERSIN K, MIN Y-L, MEINERT CL: Factors influencing publication
of research results: Follow-up of applications submitted to two
institutional review boards. JAMA 267:374–378, 1992
20. LIGHT RJ, PILLEMER DB: Summing Up: The Science of Reviewing
Research. Cambridge, Harvard University Press, 1984
21. BEGG CB, MAZUMDAR M: Operating characteristics of a rank corre-
lation test for publication bias. Biometrics 50:1088–1101, 1994
22. ROSENTHAL R: The “file-drawer problem” and tolerance for null
results. Psychol Bull 86:638–641, 1979
23. GREGOIRE G, DERDERIAN F, LELORIER J: Selecting the language of
the publications included in a meta-anslysis: Is there a Tower of Babel
bias? J Clin Epidemiol 48:159–163, 1995
24. LAU J, ANTMAN EM, JIMENEZ-SILVA J, KUPELNICK B, MOSTELLER F,
CHALMERS TC: Cumulative meta-analysis of therapeutic trials for
myocardial infarction. N Engl J Med 327:248–254, 1992
25. LAU J, SCHMID CH, CHALMERS TC: Cumulative meta-analysis of
clinical trials builds evidence for exemplary medical care. J Clin
Epidemiol 48:45–57, 1995
26. KASISKE BL, KALIL RSN, MA JZ, LIAO M, KEANE WF: Effect of
antihypertensive therapy on the kidney in patients with diabetes: A
meta-regression analysis. Ann Intern Med 118:129–138, 1993
27. MAKI DD, MA JZ, LOUIS TA, KASISKE BL: Long-term effects of
antihypertensive agents on proteinuria and renal function. Arch Intern
Med 155:1073–1080, 1995
28. DE JONG PE, HEEG JE, APPERLOO AJ, DE ZEEUW D: The antiprotein-
uric effects of blood pressure-lowering agents: Differences between
nondiabetics and diabetics. J Cardiovasc Pharmacol 19(Suppl 6):S28–
S32, 1992
29. GANSEVOORT RT, SLUITER WJ, HEMMELDER MH, DE ZEEUW D, DE
JONG PE: Antiproteinuric effect of blood-pressure-lowering agents: A
meta-analysis of comparative trials. Nephrol Dial Transplant 10:1963–
1974, 1995
30. BO¨HLEN L, DE COURTEN M, WEIDMANN P: Comparative study of the
effect of ACE-inhibitors and other antihypertensive agents on pro-
teinuria in diabetic patients. Am J Hypertens 7:84S–92S, 1994
31. BERGEMANN R, WOHLER D, WEIDMANN P, BETZIN J, NAWRATH T:
Verbesserte glucoseeinstellung und mikroalbuminurie/proteinurie bei
diabetikern unter ACE-hemmer-behandlung. Schweiz Med Wochen-
schr 122:1369–1376, 1992
32. GIATRAS I, LAU J, LEVEY AS, FOR THE ANGIOTENSIN-CONVERTING-
ENZYME INHIBITION, PROGRESSIVE RENAL DISEASE STUDY GROUP:
Effect of angiotensin-converting enzyme inhibitors on the progression
of nondiabetic renal disease: a meta-analysis of randomized trials. Ann
Intern Med 127:337–345, 1997
33. VOLHARD F: Die doppelseitigen ha¨matogenen Nierenerkrankungen
(Bright’sche Krankheit), in Handbuch der Inneren Medizin, edited by
MOHR, STAEHELIN, Berlin, Springer Verlag, 1918, p S1149
34. FOUQUE D, LAVILLE M, BOISSEL JP, CHIFFLET R, LABEEUW M, ZECH
PY: Controlled low protein diets in chronic renal insufficiency:
Meta-analysis. Br Med J 304:216–220, 1992
35. KLAHR S, LEVEY AS, BECK GJ, CAGGIULA AW, HUNSICKER L, KUSEK
JW, STRIKER G: The effects of dietary protein restriction and blood-
pressure control on the progression of chronic renal disease. N Engl
J Med 330:877–884, 1994
36. PEDRINI MT, LEVEY AS, LAU J, CHALMERS TC, WANG PH: The effect
of dietary protein restriction on the progression of diabetic and
nondiabetic renal diseases: A meta-analysis. Ann Intern Med 124:627–
632, 1996
37. COUCHOUD C, LAVILLE M, BOISSEL JP: Treatment of membranous
nephropathy: A meta-analysis. Nephrol Dial Transplant 9:469–470, 1994
38. IMPERIALE TF, GOLDFARB S, BERNS JS: Are cytotoxic agents beneficial
in idiopathic membranous nephropathy? A meta-analysis of the
controlled trials. J Am Soc Nephrol 5:1553–1558, 1995
39. HOGAN SL, MULLER KE, JENNETTE JC, FALK RJ: A review of
therapeutic studies of idiopathic membranous glomerulopathy. Am J
Kidney Dis 25:862–875, 1995
40. FELSON DT, ANDERSON J: Evidence for the superiority of immuno-
suppressive drugs and prednisone over prednisone alone in lupus
nephritis. Results of a pooled analysis. N Engl J Med 311:1528–1533, 1984
41. BANSAL VK, BETO JA: Treatment of lupus nephritis: A meta-analysis
of clinical trials. Am J Kidney Dis 29:193–199, 1997
42. SCHENA FP, MONTENEGRO M, SCIVITTARO V: Meta-analysis of ran-
domised controlled trials in patients with primary IgA nephropathy
(Berger’s Disease). Nephrol Dial Transplant 5(Suppl 1):47–52, 1990
43. BLAUFOX MD, MIDDLETON ML, BONGIOVANNI J, DAVIS BR: Cost
efficacy of the diagnosis and therapy of renovascular hypertension.
J Nucl Med 37:171–177, 1996
44. NAYLOR CD, DETSKY AS, O’ROURKE K, FONBERG E: Does treatment
with essential amino acids and hypertonic glucose improve survival in
acute renal failure?: A meta-analysis. Renal Fail 10:141–152, 1987
45. BARRETT BJ, CARLISLE EJ: Metaanalysis of the relative nephrotoxicity
of high- and low-osmolality iodinated contrast media. Radiology
188:171–178, 1993
46. GLOWACKI LS, SMAILL FM: Use of immune globulin to prevent
symptomatic cytomegalovirus disease in transplant recipients—A
meta-analysis. Clin Transplant 8:10–18, 1994
47. WALKER AM, WILKINSON GS, ZAWEL J, LANES SF: Treatment efficacy
of cyclosporine in renal transplantation. J Clin Res Pharmacoepidemiol
4:161–173, 1990
48. CARRIER M, JENICEK M, PELLETIER LC: Value of monoclonal anti-
body OKT3 in solid organ transplantation: A meta-analysis. Trans-
plant Proc 24:2586–2591, 1992
49. KASISKE BL, HEIM-DUTHOY K, MA JZ: Elective cyclosporine with-
drawal after renal transplantation. A meta-analysis. JAMA 269:395–
400, 1993
50. HRICIK DE, O’TOOLE MA, SCHULAK JA, HERSON J: Steroid-free
immunosuppression in cyclosporine-treated renal transplant recipi-
ents: A meta-analysis. J Am Soc Nephrol 4:1300–1305, 1993
51. KASISKE BL, MA JZ, LOUIS TA, SWAN SK: Long-term effects of
reduced renal mass in humans. Kidney Int 48:814–819, 1995
52. PERNA A, REMUZZI G: Abnormal permeability to proteins and
glomerular lesions: A meta-analysis of experimental and human
studies. Am J Kidney Dis 27:34–41, 1996
53. LEIBOVICI L, WYSENBEEK AJ: Single-dose treatment of urinary tract
infections with and without antibody-coated bacteria: A meta-analysis
of controlled trials. (letter) J Infect Dis 163:928–929, 1991
54. JERNIGAN JA, FARR BM: Short-course therapy of catheter-related
Staphylococcus aureus bacteremia: A meta-analysis. Ann Intern Med
119:304–311, 1993
55. KELLER F, ERDMANN K, GIEHL M, BUETTNER P: Nonparametric
meta-analysis of published data on kidney-function dependence of
pharmacokinetic parameters for the aminoglycoside netilmicin. Clin
Pharmacokinet 25:71–79, 1993
56. LABRECQUE M, DOSTALER LP, ROUSSELLE R, NGUYEN T, POIRIER S:
Efficacy of nonsteroidal anti-inflammatory drugs in the treatment of
acute renal colic. A meta-analysis. Arch Intern Med 154:1381–1387, 1994
57. RAO JK, WEINBERGER M, ODDONE EZ, ALLEN NB, LANDSMAN P,
FEUSSNER JR: The role of antineutrophil cytoplasmic antibody (c-
ANCA) testing in the diagnosis of Wegener granulomatosis. A
literature review and meta-analysis. Ann Intern Med 123:925–932, 1995
58. MASSY ZA, MA JZ, LOUIS TA, KASISKE BL: Lipid-lowering therapy in
patients with renal disease. Kidney Int 48:188–198, 1995
Kasiske: Meta-analysis as a clinical tool in nephrology 825
